Kanbi  Pharma  Teknoloji  Limite

Rezilta klinik pozitif Roche 'pi bon nan klas' potansyèl ti molekil te anonse

Jul 22, 2024

Nan dat 18 jiyè 2024, Roche te anonse rezilta pozitif Faz 1 esè klinik li nan ti molekil oral CT-996 pou pèdi pwa. Done yo te montre ke pèt pwa mwayèn nan sijè obèz san dyabèt tip 2 apre yo fin resevwa tretman CT-996 pou 4 semèn te 6.1% (p.<0.001), which was clinically significant. The complete research data is expected to be announced at the upcoming medical conference.
Esè CT-996-201 pibliye fwa sa a se yon etid faz I sou plizyè pati, milti kòwòt, owaza, doub avèg, ki kontwole plasebo, yon sèl ak plizyè dòz, ki vize pou evalye sekirite, tolerans, farmakokinetik ak farmakodinamik. nan CT-996 nan adilt ki twò gwo oswa obèz ak oswa san dyabèt tip 2.
Analiz te montre ke apre 4 semèn, pasyan ki nan gwoup CT-996 la te pèdi 7.3% nan pwa kò yo, pandan ke moun ki nan gwoup plasebo a te pèdi 1.2%. Diferans ki genyen ant de gwoup yo te klinikman enpòtan (valè diferans 6.1%, p<0.001). Pharmacokinetic data supports the once daily oral administration regimen of CT-996. In addition, the research results also indicate that the levels of CT-996 in the blood of subjects were not significantly affected during fasting or after standardized high-fat meals. Therefore, the administration of CT-996 may not require consideration of meal time, making it potentially more flexible to administer. Based on the research data, Roche expects CT-996 to not only be used for blood glucose control and weight loss treatment, but also as an oral weight maintenance therapy for patients after receiving injectable weight loss therapy.

goTop